Invasive lobular breast carcinoma with diffuse gastrointestinal metastases: a visual diagnostic pitfall [0.03%]
弥漫性胃肠道转移的侵袭性乳腺导管癌：一种视觉诊断陷阱
Jerry H Rose,Shaya Noorian,Nima Sharifai et al.
Jerry H Rose et al.
Invasive lobular carcinoma (ILC) of the breast demonstrates a distinct infiltrative growth pattern and a predilection for metastasis to the gastrointestinal tract, often without forming discrete masses. We report on a 64-year-old woman with...
Case Reports
The oncologist. 2026 Mar 9;31(4):oyag107. DOI:10.1093/oncolo/oyag107 2026
Cardiac Safety Profiles of First-Generation vs. Second-Generation BTK Inhibitors: A Meta-Analysis [0.03%]
第一代和第二代BTK抑制剂的心脏安全性分析：一项 meta 分析
Ali Mushtaq,Eman Nayaz Ahmed,Roaa Aljumaa et al.
Ali Mushtaq et al.
Background: The first-generation Bruton's tyrosine kinase inhibitor (BTKi), ibrutinib, is associated with significant cardiotoxicity. Second-generation agents were developed to mitigate this risk and offer an improved saf...
Dynamic Cytogenetic Evolution in Multiple Myeloma: Prognostic Implications from Diagnosis to First Relapse [0.03%]
多发性骨髓瘤的动态细胞遗传学进化：从诊断到首次复发的预后意义
Qi Chen,Tian Tian,Yu Shi et al.
Qi Chen et al.
Background: Cytogenetic abnormalities (CAs) in multiple myeloma (MM) are traditionally assessed statically at diagnosis, but longitudinal monitoring reveals dynamic clonal evolution, particularly during relapse. In Asian ...
A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma [0.03%]
紫杉烷类化疗药物治疗小肠腺癌的回顾性分析
Mir Lim,Nikhil Grandhi,Preksha Shah et al.
Mir Lim et al.
Background: Small bowel adenocarcinoma (SBA) is molecularly distinct from colorectal and gastric cancers, yet treatment typically parallels colorectal cancer. We evaluated the activity of taxane-based therapy in the large...
Questioning the association between prophylactic antibiotics and improved prognosis in gastric cancer immunotherapy [0.03%]
胃癌免疫治疗与预防性抗生素相关性的再思考
Yusuf Ilhan,Tolga Kosecı
Yusuf Ilhan
Disparities in the diagnosis and management of exocrine pancreatic insufficiency in resectable vs metastatic pancreatic cancer [0.03%]
可切除与转移性胰腺癌患者外分泌性胰腺功能不全的诊断和管理差异
Peiyun Ni,Christian Baglini,Jessica Meurer et al.
Peiyun Ni et al.
Background: Exocrine pancreatic insufficiency (EPI), a common complication of pancreatic cancer (PC), reduces quality of life and may shorten survival. While pancreatic enzyme replacement therapy (PERT) improves symptoms ...
Resilience in Symptom Response to Cancer Treatment: A New Lens for Examining Variable Symptom Trajectories in Older Adults with Advanced Cancer [0.03%]
癌症治疗的症候反应韧性：一种观察老年晚期癌症患者的症候轨迹的新视角
Zhihong Zhang,Eva Culakova,Kah Poh Loh et al.
Zhihong Zhang et al.
Background: Symptom trajectories vary among patients during cancer treatment. The National Institutes of Health resilience model, which defines resilience as the ability to resist, recover, or grow from stressors, may be ...
Lenvatinib combined with immune checkpoint inhibitors for unresectable, recurrent, or metastatic hepatocellular carcinoma: A real-world study [0.03%]
仑伐替尼联合免疫检查点抑制剂治疗不可切除、复发或转移性肝细胞癌的疗效及安全性：真实世界研究
Huifang Kong,Yan Chen,Hong Li et al.
Huifang Kong et al.
Background: To investigate the outcomes of combined lenvatinib plus immune checkpoint inhibitors (ICIs) in patients with unresectable, recurrent, or metastatic hepatocellular carcinoma (HCC) in a real-world setting. ...
Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection [0.03%]
吉西他滨联合白蛋白结合型紫杉醇后二线化疗用于转移性胰腺癌：比较疗效和人工智能指导的治疗选择
Letizia Procaccio,Guido Giordano,Federico Nichetti et al.
Letizia Procaccio et al.
Background: International guidelines recommend 5FU/LV, Nal-IRI + 5FU/LV, FOLFIRI, FOLFOX, or (m)FOLFIRINOX as second-line (2L) chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after failu...
Observational Study
The oncologist. 2026 Mar 9;31(4):oyag085. DOI:10.1093/oncolo/oyag085 2026